APA (7th ed.) Citation

Huang, D., Luo, Z., Gong, X., Zou, K., Peng, Y., & Zeng, S. Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: Evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Huang, Duoqin, Zixin Luo, Xi Gong, Kang Zou, Yu Peng, and Shaoying Zeng. Post Marketing Safety Assessment of the Novel Postpartum Depression Drug, Zuranolone: Evidence from Real-world Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System. Frontiers Media S.A.

MLA (9th ed.) Citation

Huang, Duoqin, et al. Post Marketing Safety Assessment of the Novel Postpartum Depression Drug, Zuranolone: Evidence from Real-world Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System. Frontiers Media S.A.